A
Alcista
Alcista · 25%LH
$255.84
Precio del escenario
$323.750
+0.615 (+0.19%)Al cierre
Loading chart…
- Máximo
- 325.000
- Apertura
- 319.100
- Precio medio ponderado por volumen
- 322.15
- Volumen
- 566.73K
- Capitalización
- 17.27B
- Mínimo
- 317.710
- Importe
- 182.57M
- EV/EBITDA, TTM
- 12.54
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
Análisis de IA of Labcorp Holdings Inc (LH)
ComprarLaboratory Corporation of America Holdings (LH) is a good buy right now due to its current price of $317.95, which is below the average analyst price target of $365 to $380, indicating significant upside potential. The stock has shown a year-to-date change of +26.34%, reflecting strong performance. However, the upcoming CMS rate cuts pose a risk, potentially reducing revenue by up to 1.2% if fully implemented, which is a key factor to monitor.
Recomendaciones de analistas (19)
-5.96% Potencial de caída
Comprar
13 Comprar
6 Mantener
0 Vender
Actual: 323.75
Mínimo
270.00
Promedio
304.45
Máximo
325.00
Truist
Comprar
$365
2026-09-21
Truist
2026-09-21
Precio objetivo
$365
Comprar
UBS
Comprar
$380
2026-09-11
UBS
2026-09-11
Precio objetivo
$380
Comprar
Barclays
Equal Weight
$330
2026-09-11
Barclays
2026-09-11
Precio objetivo
$330
Equal Weight
Mizuho
Superar al mercado
$355
2026-08-10
Mizuho
2026-08-10
Precio objetivo
$355
Superar al mercado
Piper Sandler
Neutral
$309
2026-08-04
Piper Sandler
2026-08-04
Precio objetivo
$309
Neutral
Métricas de valoración
El PER previsto actual de Labcorp Holdings Inc (LH) es 16.16, frente a su media de 5 años de 14.96.
Escenarios de precio de Alphio AI para LH
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con LH en cartera
Cronología de eventos
Noticias
8.010-21PRnewswireLabcorp Declares $0.72 Cash Dividend Per Share
8.510-20NewsfilterMyriad Genetics Sells Prenatal Health Business to Labcorp for $210 Million
8.510-15PRnewswireLabcorp Acquires BioReference Health Assets to Expand Testing Services
9.510-14CNBCUBS Predicts Several Stocks to Exceed Earnings Expectations
9.509-30PRnewswireLabcorp to Release Q3 2026 Financial Results on October 28
Preguntas frecuentes sobre LH, respondidas por Alphio AI
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).
Laboratory Corporation of America Holdings (LH) is a good buy right now due to its current price of $317.95, which is below the average analyst price target of $365 to $380, indicating significant upside potential. The stock has shown a year-to-date change of +26.34%, reflecting strong performance. However, the upcoming CMS rate cuts pose a risk, potentially reducing revenue by up to 1.2% if fully implemented, which is a key factor to monitor.
19 analysts cover LH: 13 rate it Buy, 6 Hold and 0 Sell. The average price target is 304.45.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.